Pulocimab

(Synonyms: AK109)
Kundenbewertung

Based on 1 Customer Validation

Pulocimab (AK109) is an orally active PPARα/γ dual activator with EC50 values of 48 nM and 67 nM, respectively. Pulocimab reduces plasma glucose, improves dyslipidemia, lowers total cholesterol, and raises HDL cholesterol. Pulocimab binds VEGFR2 and blocks VEGF/VEGFR2 signaling, inhibiting angiogenesis, endothelial cell migration, and tumor cell proliferation. Pulocimab can be used for research on type 2 diabetes with dyslipidemia and advanced or metastatic solid tumors.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 98.42%
  • CAS. Nr.: 2428381-49-9
  • Molecular Weight:143.721 kDa
  • Speicherung:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Alle PPAR Isoform-spezifische Produkte anzeigen

More

Alle VEGFR Isoform-spezifische Produkte anzeigen

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00